Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 5, 2015, Pages 1374-1382

  Nguyen, Huyen T ^a   Jia, Guang ^b,c   Shah, Zarine K ^a   Pohar, Kamal ^a   Mortazavi, Amir ^a   Zynger, Debra L ^a   Wei, Lai ^a   Yang, Xiangyu ^a   Clark, Daniel ^a   Knopp, Michael V ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

bladder cancer; chemotherapeutic response; k means clustering; pharmacokinetic parameters

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; COMORBIDITY; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EARLY DIAGNOSIS; FEMALE; HUMAN; K MEANS CLUSTERING; MALE; MEASUREMENT ACCURACY; MICROCIRCULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHARMACOKINETICS; PRIORITY JOURNAL; RADIOFREQUENCY; RECEIVER OPERATING CHARACTERISTIC; RELAXATION TIME; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; AGED; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ANTINEOPLASTIC AGENT; CISPLATIN; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84927697411     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24663     Document Type: Article

References (24)

1. Griffiths TR,. Current perspectives in bladder cancer management. Int J Clin Pract 2013; 67: 435-448.
2. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK,. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-2177.
3. Chang JS, Lara PN Jr, Pan CX,. Progress in personalizing chemotherapy for bladder cancer. Adv Urol 2012; 2012: 364919.
4. Barentsz JO, Berger-Hartog O, Witjes JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998; 207: 791-797.
5. Dobson MJ, Carrington BM, Collins CD, et al. The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging. Clin Radiol 2001; 56: 94-98.
6. Schrier BP, Peters M, Barentsz JO, Witjes JA,. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006; 49: 698-703.
7. Yoshida S, Koga F, Kobayashi S, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012; 83: e21-e27.
8. Chikui T, Kitamoto E, Kawano S, et al. Pharmacokinetic analysis based on dynamic contrast-enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer. J Magn Reson Imaging 2012; 36: 589-597.
9. Jung SH, Heo SH, Kim JW, et al. Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging 2012; 35: 110-116.
10. Kim HS, Kim CK, Park BK, Huh SJ, Kim B,. Evaluation of therapeutic response to concurrent chemoradiotherapy in patients with cervical cancer using diffusion-weighted MR imaging. J Magn Reson Imaging 2013; 37: 187-193.
11. Oberholzer K, Menig M, Pohlmann A, et al. Rectal cancer: Assessment of response to neoadjuvant chemoradiation by dynamic contrast-enhanced MRI. J Magn Reson Imaging 2013; 38: 119-126.
12. Rose CJ, Mills SJ, O'Connor JP, et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009; 62: 488-499.
13. Andersen EK, Kristensen GB, Lyng H, Malinen E,. Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers. Acta Oncol 2011; 50: 859-865.
14. Baudelet C, Gallez B,. Cluster analysis of BOLD fMRI time series in tumors to study the heterogeneity of hemodynamic response to treatment. Magn Reson Med 2003; 49: 985-990.
15. Lee SH, Kim JH, Kim KG, Park JS, Park SJ, Moon WK,. Optimal clustering of kinetic patterns on malignant breast lesions: comparison between K-means clustering and three-timepoints method in dynamic contrast-enhanced MRI. Conf Proc IEEE Eng Med Biol Soc 2007; 2007: 2089-2093.
16. Srinivasan A, Galban CJ, Johnson TD, Chenevert TL, Ross BD, Mukherji SK,. Utility of the k-means clustering algorithm in differentiating apparent diffusion coefficient values of benign and malignant neck pathologies. AJNR Am J Neuroradiol 2010; 31: 736-740.
17. Nguyen HT, Pohar KS, Jia G, et al. Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging. Invest Radiol 2014; 49: 390-396.
18. Krautmacher C, Willinek WA, Tschampa HJ, et al. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T-initial experience. Radiology 2005; 237: 1014-1019.
19. Londy FJ, Lowe S, Stein PD, et al. Comparison of 1.5 and 3.0 T for contrast-enhanced pulmonary magnetic resonance angiography. Clin Appl Thromb Hemost 2012; 18: 134-139.
20. Willinek WA, Gieseke J, Kukuk GM, et al. Dual-source parallel radiofrequency excitation body MR imaging compared with standard MR imaging at 3.0 T: initial clinical experience. Radiology 2010; 256: 966-975.
21. Yang X, Liang J, Heverhagen JT, et al. Improving the pharmacokinetic parameter measurement in dynamic contrast-enhanced MRI by use of the arterial input function: theory and clinical application. Magn Reson Med 2008; 59: 1448-1456.
22. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ,. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991; 15: 621-628.
23. Aravind H, Rajgopal C, Soman KP,. A simple approach to clustering in Excel. Int J Comput Appl 2010; 11: 19-25.
24. Pham DT, Dimov SS, Nguyen CD,. Selection of k in k-means clustering. Mech Eng Sci 2004; 219: 103-119.